These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 28125180)
41. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881 [TBL] [Abstract][Full Text] [Related]
42. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Coleman CI; Peacock WF; Bunz TJ; Alberts MJ Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814 [TBL] [Abstract][Full Text] [Related]
43. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism. Coleman CI; Bunz TJ; Turpie AGG Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322 [TBL] [Abstract][Full Text] [Related]
44. Benefit, risk and cost of new oral anticoagulants and warfarin in atrial fibrillation; A multicriteria decision analysis. Mendoza-Sanchez J; Silva F; Rangel L; Jaramillo L; Mendoza L; Garzon J; Quiroga A PLoS One; 2018; 13(5):e0196361. PubMed ID: 29723207 [TBL] [Abstract][Full Text] [Related]
45. Comparison of Direct Oral Anticoagulants and Warfarin in the Treatment of Deep Venous Thrombosis in the Chronic Phase. Wakakura S; Hara F; Fujino T; Hamai A; Ohara H; Kabuki T; Harada M; Ikeda T Int Heart J; 2018 Jan; 59(1):126-135. PubMed ID: 29279522 [TBL] [Abstract][Full Text] [Related]
46. Successful use of rivaroxaban in postoperative deep vein thrombosis of the lower limb following instability with warfarin: a case report. Schiavoni M; Coluccia A J Med Case Rep; 2016 Oct; 10(1):276. PubMed ID: 27716428 [TBL] [Abstract][Full Text] [Related]
47. Economic evaluation of prescribing conventional and newer oral anticoagulants in older adults. Hasan SS; Kow CS; Curley LE; Baines DL; Babar ZU Expert Rev Pharmacoecon Outcomes Res; 2018 Aug; 18(4):371-377. PubMed ID: 29741099 [TBL] [Abstract][Full Text] [Related]
48. The cost-utility of dabigatran etexilate compared with warfarin in treatment and extended anticoagulation of acute VTE in the UK. Jugrin AV; Ustyugova A; Urbich M; Lamotte M; Sunderland T Thromb Haemost; 2015 Oct; 114(4):778-92. PubMed ID: 26272227 [TBL] [Abstract][Full Text] [Related]
49. Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis. Lee J; Nakanishi R; Li D; Shaikh K; Shekar C; Osawa K; Nezarat N; Jayawardena E; Blanco M; Chen M; Sieckert M; Nelson E; Billingsley D; Hamal S; Budoff MJ Am Heart J; 2018 Dec; 206():127-130. PubMed ID: 30227941 [TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands. Heisen M; Treur MJ; Heemstra HE; Giesen EBW; Postma MJ J Med Econ; 2017 Aug; 20(8):813-824. PubMed ID: 28521540 [TBL] [Abstract][Full Text] [Related]
51. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation. Piccini JP; Hellkamp AS; Washam JB; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hankey GJ; Hacke W; Mahaffey KW; Nessel CC; Singer DE; Fox KA; Patel MR Circulation; 2016 Jan; 133(4):352-60. PubMed ID: 26673560 [TBL] [Abstract][Full Text] [Related]
52. Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting. Morais J; Aguiar C; McLeod E; Chatzitheofilou I; Fonseca Santos I; Pereira S Rev Port Cardiol; 2014 Sep; 33(9):535-44. PubMed ID: 25241380 [TBL] [Abstract][Full Text] [Related]
53. The Outcome of Anticoagulation on Endovenous Laser Therapy for Superficial Venous Incompetence. Vatish J; Iqbal N; Rajalingam VR; Tiwari A Vasc Endovascular Surg; 2018 May; 52(4):245-248. PubMed ID: 29448895 [TBL] [Abstract][Full Text] [Related]
54. Rivaroxaban in the Prevention of Stroke and Systemic Embolism in Patients with Non-Valvular Atrial Fibrillation: Clinical Implications of the ROCKET AF Trial and Its Subanalyses. Spencer RJ; Amerena JV Am J Cardiovasc Drugs; 2015 Dec; 15(6):395-401. PubMed ID: 26062914 [TBL] [Abstract][Full Text] [Related]
55. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905 [TBL] [Abstract][Full Text] [Related]
56. Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin. Weeda ER; Wells PS; Peacock WF; Fermann GJ; Baugh CW; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI Intern Emerg Med; 2017 Apr; 12(3):311-318. PubMed ID: 27757790 [TBL] [Abstract][Full Text] [Related]
57. Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban. Merli GJ; Hollander JE; Lefebvre P; Laliberté F; Raut MK; Olson WH; Pollack CV Hosp Pract (1995); 2015; 43(2):85-93. PubMed ID: 25791984 [TBL] [Abstract][Full Text] [Related]
58. Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). Washam JB; Hellkamp AS; Lokhnygina Y; Piccini JP; Berkowitz SD; Nessel CC; Becker RC; Breithardt G; Fox KAA; Halperin JL; Hankey GJ; Mahaffey KW; Singer DE; Patel MR; Am J Cardiol; 2017 Aug; 120(4):588-594. PubMed ID: 28645473 [TBL] [Abstract][Full Text] [Related]
59. Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital. Cieri NE; Kusmierski K; Lackie C; Van Opdorp A; Hassan AK Pharmacotherapy; 2017 Feb; 37(2):170-176. PubMed ID: 28028830 [TBL] [Abstract][Full Text] [Related]
60. Poor response to rivaroxaban in nephrotic syndrome with acute deep vein thrombosis: A case report. Li Y; Chen Y; Qi X; Hu B; Du Q; Qian Y Medicine (Baltimore); 2019 Aug; 98(31):e16585. PubMed ID: 31374026 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]